Feb 16, 2016 8:00am EST Tonix Pharmaceuticals Reports Top Line Results From Phase 2 Proof-of-Concept Clinical Study of TNX-201 in Episodic Tension-Type Headache
Feb 2, 2016 7:05am EST Tonix Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference
Dec 23, 2015 7:00am EST Tonix Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD)
Dec 8, 2015 7:00am EST Tonix Pharmaceuticals Completes Enrollment in Phase 2 Clinical Study of TNX-201 in Episodic Tension-Type Headache
Dec 7, 2015 7:00am EST Tonix Pharmaceuticals and U.S. Department of Defense Military Developer in Partnership to Expand Efforts to Examine TNX-102 SL for Post-Traumatic Stress Disorder
Dec 1, 2015 7:00am EST Tonix Pharmaceuticals to Participate in Fireside Chat at the Oppenheimer 26th Annual Healthcare Conference
Nov 10, 2015 8:30am EST Tonix Pharmaceuticals Presents Additional Data on Tonmya(TM) Demonstrating Improvements in Sleep, Pain, and Other Outcomes in Fibromyalgia at 2015 ACR/ARHP Annual Meeting
Nov 9, 2015 7:00am EST Tonix Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Programs Update
